Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated:  3/5/2018
Octapharma Research Site
mi
from
Loma Linda, CA
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated: 3/5/2018
Octapharma Research Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated:  3/5/2018
Octapharma Research Site
mi
from
Philadelphia, PA
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated: 3/5/2018
Octapharma Research Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated:  3/5/2018
Octapharma Research Site
mi
from
Pittsburgh, PA
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated: 3/5/2018
Octapharma Research Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated:  3/5/2018
Octapharma Research Site
mi
from
Nashville, TN
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.
Status: Enrolling
Updated: 3/5/2018
Octapharma Research Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders
Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders
Status: Enrolling
Updated:  3/6/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders
Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders
Status: Enrolling
Updated: 3/6/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
The Captivator EMR Registry
An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus
Status: Enrolling
Updated:  3/6/2018
Mayo Clinic
mi
from
Jacksonville, FL
The Captivator EMR Registry
An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus
Status: Enrolling
Updated: 3/6/2018
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
The Captivator EMR Registry
An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus
Status: Enrolling
Updated:  3/6/2018
The Mayo Clinic
mi
from
Rochester, MN
The Captivator EMR Registry
An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus
Status: Enrolling
Updated: 3/6/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
The Captivator EMR Registry
An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus
Status: Enrolling
Updated:  3/6/2018
University Hospital Leuven
mi
from
Leuven,
The Captivator EMR Registry
An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus
Status: Enrolling
Updated: 3/6/2018
University Hospital Leuven
mi
from
Leuven,
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Weill-Cornell Medical College
mi
from
New York, NY
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated:  3/7/2018
Yale University
mi
from
New Haven, CT
Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Status: Enrolling
Updated: 3/7/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Status: Enrolling
Updated:  3/7/2018
UAB Continence Clinic at The Kirklin Clinic
mi
from
Birmingham, AL
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Vitamin D Supplementation in Older Adults With Urinary Incontinence
Status: Enrolling
Updated: 3/7/2018
UAB Continence Clinic at The Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Collaborative Research Group for Necrotizing Enterocolitis
Collaborative Research Group for Necrotizing Enterocolitis
Status: Enrolling
Updated:  3/7/2018
St. Louis Children's Hospital
mi
from
Saint Louis, MO
Collaborative Research Group for Necrotizing Enterocolitis
Collaborative Research Group for Necrotizing Enterocolitis
Status: Enrolling
Updated: 3/7/2018
St. Louis Children's Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Chapel Hill, NC
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Durham, NC
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated:  3/8/2018
mi
from
Maastricht,
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)
Status: Enrolling
Updated: 3/8/2018
mi
from
Maastricht,
Click here to add this to my saved trials
A Biologic Validation of Biomarkers of Progressive NEC & Sepsis
A Biologic Sample Study for the Validation of Biomarkers of Progressive NEC & Sepsis
Status: Enrolling
Updated:  3/8/2018
R. Lawrence Moss, MD, Nationwide Children's Hospital, The Ohio State University, Karl Sylvester, MD, Stanford University, Stanford, Califorinia
mi
from
Columbus, OH
A Biologic Validation of Biomarkers of Progressive NEC & Sepsis
A Biologic Sample Study for the Validation of Biomarkers of Progressive NEC & Sepsis
Status: Enrolling
Updated: 3/8/2018
R. Lawrence Moss, MD, Nationwide Children's Hospital, The Ohio State University, Karl Sylvester, MD, Stanford University, Stanford, Califorinia
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
University of Chicago
mi
from
Chicago, IL
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Indiana University School of Medicine
mi
from
Indianapolis, IN
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Beth Israel Med Ctr
mi
from
New York, NY
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Baylor College of Medicine
mi
from
Houston, TX
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Liver Institute of Virginia
mi
from
Newport News, VA
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Liver Institute of Virginia
mi
from
Newport News, VA
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Virginia Commonwealth University/McGuire DVAMC
mi
from
Richmond, VA
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Virginia Commonwealth University/McGuire DVAMC
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
UC Davis Medical Center
mi
from
Sacramento, CA
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Scripps Clinic
mi
from
San Diego, CA
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Scripps Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
University of Colorado Denver
mi
from
Aurora, CO
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Henry Ford Health System
mi
from
Detroit, MI
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
St. Louis University
mi
from
Saint Louis, MO
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
St. Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Liver Institute of Virginia
mi
from
Richmond, VA
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Liver Institute of Virginia
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Swedish Medical Center
mi
from
Seattle, WA
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Royal Prince Alfred Hospital
mi
from
Camperdown,
Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
University of Miami
mi
from
Miami, FL
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Beth Israel Med Ctr
mi
from
New York, NY
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Mcguire Dvamc
mi
from
Richmond, VA
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Mcguire Dvamc
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Scripps Clinic
mi
from
La Jolla, CA
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Indiana University Medical Center
mi
from
Indianapolis, IN
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Swedish Medical Center
mi
from
Seattle, WA
Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Henry Ford
mi
from
Novi, MI
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Henry Ford
mi
from
Novi, MI
Click here to add this to my saved trials
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Baylor College of Medicine
mi
from
Houston, TX
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Mcguire Dvamc
mi
from
Richmond, VA
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Mcguire Dvamc
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  3/9/2018
Karls-Franzens University
mi
from
Graz,
Study of INT-747 as Monotherapy in Patients With PBC
A Study of INT-747 (6-ECDCA) Monotherapy in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 3/9/2018
Karls-Franzens University
mi
from
Graz,
Click here to add this to my saved trials
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
Status: Enrolling
Updated:  3/12/2018
University of California, San Diego
mi
from
San Diego, CA
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
Status: Enrolling
Updated: 3/12/2018
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
Status: Enrolling
Updated:  3/12/2018
Indiana University
mi
from
Indianapolis, IN
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis (NASH) Treatment (FLINT) Trial
Status: Enrolling
Updated: 3/12/2018
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials